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INTRODUCTION
Collagen fibres are involved in the adhesion and trapping of platelets to exposed subendothelium at sites of vascular damage 1 . Collagen binds a number of receptors on platelets, principally glycoprotein (GP) Ia/IIa and GPVI 2 . It also indirectly binds to the platelet surface via von Willebrand factor (vWF). Under high shear conditions, vWF attached to collagen binds to the platelet receptor complex
GPIb-IX-V. Platelet velocity then decreases permitting firm attachment of collagen to GPIa/IIa, establishing platelet adhesion. Collagen further interacts with the lower affinity receptor GPVI, promoting platelet activation and thromboxane A 2 production 3 .
To date, there are approximately nineteen known genetically distinct collagen types with specialised tissue distributions 4 . Collagen Type III is the second most abundant collagen in human tissues, after Collagen Type I and is expressed in blood vessels. It is encoded by the COL3A1 gene, which is 44kb in length and contains 52 exons 5 , and is closely linked with the COL5A2 gene 6 .
Type I and Type III collagens appear together in the thickened intima of atherosclerotic lesions 7 . This plaque collagen is mainly produced by smooth muscle cells (SMCs), but can also be synthesised by endothelial cells. Fibrillar Type I and Type III collagens occupy approximately 80% of the section area in samples of restenotic lesions of the human coronary artery 7 , contributing to plaque growth and arterial lumen narrowing. Degradation of collagens by matrix metalloproteinases may overcome synthesis, resulting in plaque rupture and thrombus formation 8 .
In this study, we examined a highly polymorphic region on intron 25 of the COL3A1 gene 9 . In the absence of clear mechanistic models for the roles of alternative alleles, initial investigations of the role of genetic variability usually rely 
Genotyping
Genomic DNA was extracted from whole blood using methods previously described 15 . A 210bp fragment, containing the 15 bp repeat on intron 25, was amplified using 
Statistical Methods
The association between genotype and presentation (comparisons among the Irish ACS, stable angina and control groups) was investigated using a logistic regression.
The two primary endpoints were ACS versus control and ACS versus stable angina.
In the follow-up OPUS-TIMI-16 trial, the primary endpoint was the composite endpoint. Survival analysis considered the association between genotype and the time to first event for each of composite endpoint, MI, and the first severe, major, or minor 
RESULTS
11 different allelic forms of the COL3A1-VNTR were observed in the studies (see Table 1 ). In all of the populations, alleles 1, 2, 3 and 4 were the most common.
Analysis in the ACS and stable angina populations
The genotype frequencies in the Irish groups are shown in Table 2 . COL3A1-4 carriers had a significantly lower risk of both ACS (OR=0.57, CI=0.35-0.91) and stable angina (OR=0.35, CI=0.16-0.74) compared to controls ( Table 3 ). The increased risk conferred by allele 3 was not significant for either the stable angina or the ACS groups (Table 3) . To correct for multiple statistical testing, logistic regression treated ACS, stable angina and controls as three classes. The effect of COL3A1-4 remained significant (p=0.007) even after Bonferroni correction for the 4 major alleles (p=0.028). Comparisons between stable and unstable disease should highlight variants that increase the risk of coronary thrombus/plaque rupture against a background of atherosclerotic disease. However, the frequency of the main COL3A1 alleles was similar in the stable angina and ACS groups ( Table 3) .
Influence of baseline covariates on ischaemic endpoints and bleeding in the OPUS-
TIMI-16 trial
In the OPUS-TIMI-16 study analysis of 924 Caucasians subjects, neither age, sex nor geographical origin were significantly associated with the risk of composite events (or the risk of MI when considered alone). Severe, major, or minor bleeding occurred in 18.4% of patients during the follow-up. Genetic samples were taken from patients in the Americas (742), Europe (172) and South Africa (10). There was a significant variation in the risk of bleeding between countries and with increasing age. Influence of genotype on ischaemic endpoints and bleeding in the OPUS-TIMI-16 study and the interaction with GPIIb/IIIa antagonists Table 4 Interaction between genotype and treatment When outcomes are compared among the treated and placebo groups (Table   5) , treatment appeared to alter the impact of the COL3A1 genotype on the relative risk of the composite endpoint. The increased risk of COL3A1 allele 3 (versus noncarrier) was evident in those receiving the GPIIb/IIIa antagonist, but not amongst those receiving placebo. There was also a significant interaction between treatment For personal use only. on October 31, 2017. by guest www.bloodjournal.org From and the COL3A1 allele 1, which conferred an increased risk in patients receiving the placebo but not in those on orbofiban.
There was no interaction between COL3A1 genotype and treatment for bleeding risk, i.e. the increase in bleeding among COL3A1-3 carriers was not significantly different between placebo (RR=1.40, CI=0.75-2.60) and treated patients (RR=1.44, CI=1.01-2.07).
Covariate adjustment
Covariate adjustment helps indicate whether a variant confers its risk through known factors or by an independent pathway. We chose not to adjust for major risk factors since genetic effects are causative rather than a by-product. In the OPUS study 
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Page 12 of 23 s observations). Clearly, a larger analysis in another IIb/IIIa antagonist study is required in order to clarify the allele 3 associations in the OPUS study, and determine which of the three formally significant associations for allele 3 are true positive findings.
What are the implications of the findings for our understanding of how collagen synthesis and platelet signalling at diseased sites contributes to disease? It is unlikely that the intronic VNTR polymorphism is itself causal, since it does not modify the protein sequence, and is not close to the promoter of the gene. Therefore, it is likely to be in strong disequilibrium 10 with (i.e. very strongly associated with) unidentified causative genetic factor(s) in either the promoter or the protein-coding sequences. Further elucidation will require analyses in both the promoter and protein coding regions. The formation of the fibrous cap on an atherosclerotic plaque reflects a balance between the rate of synthesis of collagens and other connective tissue proteins, and the rate of synthesis of collagen degrading enzymes such as metalloproteinases 21 . In addition to a difference in the propensity to lay down collagen (perhaps through the influence of a promoter variant), gene variants may influence the propensity for degradation (perhaps through a structural variant).
Alternatively, the risk may be mediated through platelet signalling, since our data suggests that the COL3A1-3 variant may impact on the response to an anti-platelet agent.
Regardless of the mechanism, this genetic study highlights the importance of vessel wall components in determining the risk of coronary events. It will be of interest to determine whether genetic variation in other vascular wall components comprise an important element of cardiovascular risk. articles must include digital object identifier (DOIs) and date of initial publication. 
